/

CRVO

CervoMed Inc.Closed

2.27−0.24 −9.56%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.24 −1.32%

Open

2.50

Prev close

2.51

Day range

2.172.53

52-week range

2.1310.00

Volume

535.90K1.66×

Mkt cap

34.32M

P/E ttm

—

Fwd P/E

-1.64

EPS ttm

-3.21

Div yield

0.00%

Earnings

Aug 10, 2026

From 52w high

−77.30%

Price Chart

Yahoo Finance · delayed

CRVOOct 13, 2026O 2.50H 2.53L 2.17C 2.27−0.24 (−9.56%)Vol 539.30K

SMA 502.71
SMA 2003.87

1Y change −71.66% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CRVO CervoMed Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −32.04%
1 month: −11.67%
3 months: −26.30%
6 months: −43.81%
Year to date: −71.27%
1 year: −71.66%

Valuation & ownership

Market cap: 34.32M
Enterprise value: 9.38M
P/E (ttm): —
Forward P/E: -1.64
PEG ratio: —
Price / book: 1.34
Price / sales (ttm): 103.59
EV / EBITDA: —
EPS (ttm): -3.21
EPS (forward): -1.39
Beta (5y monthly): -4.30
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 15.12M
Float: 9.60M
Short % of float: 10.96%
Short ratio (days): 7.46
Held by insiders: 26.43%
Held by institutions: 22.28%
Avg volume (3m): 321.88K
50-day average: 2.72
200-day average: 3.90
52-week change: −71.66%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 35.7
vs 50-day SMA: −16.37%
vs 200-day SMA: −41.37%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.40%
Realised vol (20d, ann.): 115.8%
From 52-week high: −77.30%
From 52-week low: +6.57%

ANR

Analyst Consensus

5 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

15.00

+560.79% implied

Low 7.00Median 15.00High 25.00

Recommendation trend

Now6 / 0 / 0
1m ago6 / 0 / 0
2m ago

DES

About CervoMed Inc.

Yahoo Finance profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 15
Headquarters: Boston, MA, United States
Website: cervomed.com
Officers: Dr. John J. Alam M.D. Co-Founder, CEO, President & Director
Dr. Sylvie L. Gregoire Pharm.D. Co-Founder & Director
Mr. William Robert Elder J.D. CFO, General Counsel & Corporate Secretary
Ms. Kelly Blackburn M.H.A. Executive Vice President of Clinical Development

SEAS

Seasonality · CRVO

2008–2026 · monthly returns

Strongest month Mar +23.62%Weakest month Jun −13.48%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-34.8	-22.5	-1.3	-6.3	-15.7	-0.3	-16.8	1.9	12.9	-23.6			−71.3%
2025	-3.4	-0.9	308.5	-1.0	-20.3	-12.9	31.2	16.6	-15.9	-12.9	41.0	-20.5	+237.6%
2024	9.3	64.6	69.7	4.2	-22.0	-9.6	-24.1	43.2	-21.6	-6.5	-20.9	-78.3	−69.3%
2023	30.0	-12.6	-27.8	-7.5	1.0	-13.9	-6.9	26.9	-22.0	87.2	13.3	-22.1	+0.5%
2022	-12.9	-14.8	8.7	-50.6	32.8	-18.6	-3.4	3.9	-20.1	-10.3	35.4	-22.2	−67.4%
2021	42.5	0.9	-20.0	-18.5	-6.7	4.3	-24.7	7.3	-13.6	-11.8	-17.8	-16.2	−61.2%
2020	-6.5	-4.7	-22.0	56.3	160.0	-24.6	17.3	-14.8	-14.3	-2.4	-7.3	5.3	+73.9%
2019	10.6	67.3	0.8	-20.2	9.1	-11.8	-20.7	-13.3	-5.6	-54.6	-51.2	12.2	−76.9%
2018	-48.3	1.6	-11.3	0.0	-10.9	-6.1	-19.6	2.7	13.2	-11.6	-26.3	-52.6	−88.8%
2017	33.6	6.0	24.7	-24.1	-9.9	-14.7	-20.6	-3.2	-7.3	-11.4	-8.2	-12.6	−47.8%
2016	24.0	-15.3	4.8	-9.1	-10.0	-11.1	12.5	-2.8	-20.0	-42.6	-45.3	2.7	−77.4%
2015	0.0	-9.4	-18.1	14.3	-16.8	-28.3	-10.2	-16.7	-28.0	-38.9	-9.1	100.0	−69.7%
2014	0.0	0.0	100.0	-21.7	-14.9	4.5	-9.6	-12.7	7.6	-2.8	5.8	-9.6	+10.0%
2013	-36.8	33.3	-6.3	-6.7	42.9	-25.0	13.3	-52.9	37.5	-36.4	28.6	-66.7	−84.2%
2012	-10.0	15.6	-13.5	13.3	-5.9	-18.8	25.6	-30.6	23.5	-45.2	-34.8	26.7	−62.0%
2011	-23.4	-2.0	10.4	79.2	0.0	-26.3	-14.3	0.0	6.7	17.2	-28.0	-7.4	−21.9%
2010	-18.2	3.3	-7.9	-8.6	15.6	-45.4	10.9	-21.4	-43.2	4.0	1.9	20.8	−71.6%
2009	-5.7	-3.3	0.7	2.7	15.3	15.6	7.5	-4.7	11.7	10.9	-17.3	7.1	+41.5%
2008						0.0	0.0	-0.5	3.0	-2.9	-25.1	6.7	−20.5%

INSD

Insider Activity · CRVO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 10, 2026	Boger Joshua SDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.44 per share.	955.4K	$2.33M
Nov 17, 2025	Elder William RobertGeneral Counsel	Purchase at price 8.32 - 8.45 per share.	3.5K	$29.25K
Nov 17, 2025	Winton MatthewOfficer	Purchase at price 7.95 - 8.43 per share.	5K	$41.43K
Nov 16, 2025	Gregoire Sylvie LDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 8.46 per share.	21.6K	$182.74K
Nov 16, 2025	Alam John JChief Executive Officer	Purchase at price 8.46 per share.	21.6K	$182.74K
Nov 13, 2025	Gregoire Sylvie LDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 7.51 - 7.57 per share.	7.8K	$59.10K
Nov 13, 2025	Winton MatthewOfficer	Purchase at price 7.57 per share.	10K	$75.70K
Nov 13, 2025	Alam John JChief Executive Officer	Purchase at price 7.51 - 7.57 per share.	7.8K	$59.10K
Nov 11, 2025	Gregoire Sylvie LDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 7.35 per share.	5.6K	$40.81K
Nov 11, 2025	Elder William RobertGeneral Counsel	Purchase at price 7.44 per share.	3.5K	$26.04K
Nov 11, 2025	Alam John JChief Executive Officer	Purchase at price 7.35 per share.	5.6K	$40.81K
May 13, 2025	Elder William RobertGeneral Counsel	Purchase at price 8.46 per share.	4.2K	$35.81K

CRVO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CRVO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About CervoMed Inc.

Seasonality · CRVO

Insider Activity · CRVO

Congress Trades · CRVO

Investors Holding CRVO

Investors Holding CRVO

Congress Trades · CRVO

Insider Activity · CRVO

Seasonality · CRVO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About CervoMed Inc.

Financial Snapshot

Earnings & Dividends

News